Literature DB >> 27812743

Glomerular hyperfiltration in children with cancer: prevalence and a hypothesis.

Neha S Kwatra1,2, Holly J Meany3, Sunil J Ghelani4, David Zahavi5, Nayan Pandya1, Massoud Majd6.   

Abstract

BACKGROUND: Glomerular hyperfiltration has recently been reported in children with malignancies and has been attributed to increased solute from breakdown of tumor tissues.
OBJECTIVE: To evaluate the prevalence of hyperfiltration in the pediatric oncology population and explore its pathophysiological mechanism.
MATERIALS AND METHODS: Tc-99 m diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) examinations (437 studies) and medical records of 177 patients <21 years of age diagnosed with a malignancy between January 2005 and October 2013 were retrospectively reviewed. Hyperfiltration was defined as a GFR ≥ 160 ml/min/1.73 m2.
RESULTS: Seventy-seven (43.5%) patients had hyperfiltration in at least one GFR exam. A significantly higher percentage of patients with central nervous system (CNS) tumors (63.6%) had hyperfiltration when compared to other tumor types (27.3%, P < 0.001). No association was found between hyperfiltration and age, gender, race or bone marrow involvement. There was a significant trend toward decreasing hyperfiltration after the second cycle of chemotherapy (P = 0.006) and a significant increase in subjects with low GFR (<100 ml/min/1.73 m2) with increasing number of cycles of chemotherapy (P = 0.005).
CONCLUSION: Glomerular hyperfiltration is common in children with malignancies at diagnosis and during initial cycles of chemotherapy. It is particularly prevalent in patients with central nervous tumors, which are frequently smaller in volume. Therefore, the pathophysiological mechanism of hyperfiltration cannot be explained solely on the basis of large tumor volume and subsequent cell breakdown. We hypothesize that host hypermetabolic state plays an important role in pathophysiology of hyperfiltration.

Entities:  

Keywords:  Cancer; Children; Glomerular filtration rate; Glomerular hyperfiltration; Hypermetabolism; Tc-99 m diethylenetriaminepentaacetic acid

Mesh:

Substances:

Year:  2016        PMID: 27812743     DOI: 10.1007/s00247-016-3733-5

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  19 in total

1.  Guidelines for the measurement of glomerular filtration rate using plasma sampling.

Authors:  John S Fleming; Maureen A Zivanovic; Glen M Blake; Maria Burniston; Philip S Cosgriff
Journal:  Nucl Med Commun       Date:  2004-08       Impact factor: 1.690

Review 2.  Metabolic effects of cancer.

Authors:  R G Douglas; J H Shaw
Journal:  Br J Surg       Date:  1990-03       Impact factor: 6.939

3.  Reference ranges for 51Cr-EDTA measurements of glomerular filtration rate in children.

Authors:  Glen M Blake; Natasha Gardiner; Gopinath Gnanasegaran; Sabina Dizdarevic
Journal:  Nucl Med Commun       Date:  2005-11       Impact factor: 1.690

Review 4.  Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

Authors:  Imed Helal; Godela M Fick-Brosnahan; Berenice Reed-Gitomer; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

5.  Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Authors:  Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware
Journal:  Am J Hematol       Date:  2012-12-17       Impact factor: 10.047

Review 6.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.

Authors:  Zhaoyong Li; Huafeng Zhang
Journal:  Cell Mol Life Sci       Date:  2015-10-23       Impact factor: 9.261

7.  Estimation of normal chromium-51 ethylene diamine tetra-acetic acid clearance in children.

Authors:  A Piepsz; H Pintelon; H R Ham
Journal:  Eur J Nucl Med       Date:  1994-01

Review 8.  Aspects of altered metabolism in children with cancer.

Authors:  S V Picton
Journal:  Int J Cancer Suppl       Date:  1998

9.  Glomerular filtration rate in children with solid tumors: normative values and a new method for estimation.

Authors:  J R Brandt; Craig Wong; D R Jones; C Qualls; N McAfee; E Brewer; S L Watkins
Journal:  Pediatr Hematol Oncol       Date:  2003-06       Impact factor: 1.969

Review 10.  Cancer cachexia: mediators, signaling, and metabolic pathways.

Authors:  Kenneth C H Fearon; David J Glass; Denis C Guttridge
Journal:  Cell Metab       Date:  2012-07-12       Impact factor: 27.287

View more
  5 in total

1.  Prospective pediatric study comparing glomerular filtration rate estimates based on motion-robust dynamic contrast-enhanced magnetic resonance imaging and serum creatinine (eGFR) to 99mTc DTPA.

Authors:  Sila Kurugol; Onur Afacan; Richard S Lee; Catherine M Seager; Michael A Ferguson; Deborah R Stein; Reid C Nichols; Monet Dugan; Alto Stemmer; Simon K Warfield; Jeanne S Chow
Journal:  Pediatr Radiol       Date:  2020-01-27

2.  Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?

Authors:  Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2018-10-29       Impact factor: 3.714

3.  Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!

Authors:  Pascal André; Léonore Diezi; Kim Dao; Pierre Alex Crisinel; Laura E Rothuizen; Haithem Chtioui; Laurent Arthur Decosterd; Manuel Diezi; Sandra Asner; Thierry Buclin
Journal:  Front Pediatr       Date:  2022-01-05       Impact factor: 3.418

4.  GFR Estimation After Cystatin C Reference Material Change.

Authors:  Stefanie W Benoit; Thelma Kathman; Jay Patel; Melinda Stegman; Cristina Cobb; Jonathan Hoehn; Prasad Devarajan; Edward J Nehus
Journal:  Kidney Int Rep       Date:  2020-12-07

5.  Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort.

Authors:  Riitta Niinimäki; Henri Aarnivala; Joanna Banerjee; Tytti Pokka; Kaisa Vepsäläinen; Arja Harila-Saari
Journal:  Support Care Cancer       Date:  2021-07-08       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.